22.Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.Immunopharmacol Immunotoxicol. 2016 Jun;38(3):253-6. doi: 10.3109/08923973.2016.1173057.

23. Uzun R,Yalcin AD, Celik B, Bulut T, Yalcin AN. Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone.Am J Case Rep. 2016 Sep 16;17:666-71.

24. Yalcin AD. Human(ized) Monoclonal Antibodies in Asthma: Future Perspectives. .Editorial. J Allergy Ther 7:e115. doi:10.4172/2155-6121.1000e115.

25. Aydın GÇ, Arslan E,Yalcin AD. Does the Anti-Immunoglobulin E (Anti-IgE) Treatment Increase the Risk of Infection? Canadian Respiratory Journal 2017 in press.

26. Yalcin AD. Biological Agents in Asthma therapy: An Overview.Editorial. Canadian Respiratory Journal 2017 in press.

27. Onbaşı KT, Yalcin AD. Human(ized) Monoclonal Antibodies in Asthma. Canadian Respiratory Journal 2017 in press.

28. Bulut T, Uzun R, Gunal O, Yalcin AD. Anti-IgE Monoclonal Antibody in Bronchiectasis: New Perspective . Canadian Respiratory Journal 2017 in press.

29. CİRCULATİNG ADİPOKİNECHEMERİN, İRİSİN AND IL-1Β LEVELS WERE INCREASED İN SEVERE PERSİSTENT ALLERGİC ASTHMA PATİENTS

Iris (Greek mythology) . Boström and colleagues reported increased fibronectin type III domain-containing protein 5 (FNDC5).112 amino acids and molecular weight of 12 kDa

Chemerin’s mRNA is identified at high levelsin the lung, kidney, colon, skin and liver. Chemerin was originally recognized as a chemoattractant protein mainly mediatingthe chemotaxis of plasmacytoid dendriticcells(CD80) and natural killer cells(NKC,CD16,CD56). 163 amino acid precursor(pro-chemerin)

Prof. Dr. Tse Wen Chang

adidyal@yahoo.comhttps://www.researchgate.net/profile/Arzu_Yalcin